{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:12:32Z","timestamp":1790802752029,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700456"],"award-info":[{"award-number":["81700456"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010248","name":"Zhejiang Province Public Welfare Technology Application Research Project","doi-asserted-by":"publisher","award":["2018KY104"],"award-info":[{"award-number":["2018KY104"]}],"id":[{"id":"10.13039\/501100010248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10620-020-06208-3","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T05:07:55Z","timestamp":1584680875000},"page":"568-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Deoxycholic Acid-Induced Gut Dysbiosis Disrupts Bile Acid Enterohepatic Circulation and Promotes Intestinal Inflammation"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8476-6625","authenticated-orcid":false,"given":"Mengque","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsha","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"6208_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769\u20132778.","journal-title":"Lancet"},{"key":"6208_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u2013727.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6208_CR3","doi-asserted-by":"publisher","first-page":"313\u2013321e2","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313\u2013321e2.","journal-title":"Gastroenterology"},{"key":"6208_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/gutjnl-2012-303954","volume":"62","author":"D Knights","year":"2013","unstructured":"Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62:1505\u20131510.","journal-title":"Gut"},{"key":"6208_CR5","doi-asserted-by":"publisher","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","volume":"312","author":"JBJ Ward","year":"2017","unstructured":"Ward JBJ, Lajczak NK, Kelly OB, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017;312:G550\u2013G558.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"6208_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/ibd\/izz186","volume":"26","author":"H Khalili","year":"2020","unstructured":"Khalili H. The changing epidemiology of inflammatory bowel disease: what goes up may come down. Inflamm Bowel Dis. 2020;26:591\u2013592.","journal-title":"Inflamm Bowel Dis"},{"key":"6208_CR7","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3748\/wjg.v23.i12.2124","volume":"23","author":"DC Rapozo","year":"2017","unstructured":"Rapozo DC, Bernardazzi C, de Souza HS. Diet and microbiota in inflammatory bowel disease: the gut in disharmony. World J Gastroenterol. 2017;23:2124\u20132140.","journal-title":"World J Gastroenterol"},{"key":"6208_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00365521003702734","volume":"45","author":"A Bajor","year":"2010","unstructured":"Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol. 2010;45:645\u2013664.","journal-title":"Scand J Gastroenterol"},{"key":"6208_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41385-019-0162-4","volume":"12","author":"ML Chen","year":"2019","unstructured":"Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019;12:851\u2013861.","journal-title":"Mucosal Immunol"},{"key":"6208_CR10","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1039\/C8FO01143E","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L, Dong W, Wang S, et al. Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis. Food Funct. 2018;9:5588\u20135597.","journal-title":"Food Funct"},{"key":"6208_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1002\/ijc.30643","volume":"140","author":"H Cao","year":"2017","unstructured":"Cao H, Xu M, Dong W, et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int J Cancer. 2017;140:2545\u20132556.","journal-title":"Int J Cancer"},{"key":"6208_CR12","first-page":"2481418","volume":"2018","author":"S Zhao","year":"2018","unstructured":"Zhao S, Gong Z, Du X, et al. Deoxycholic acid-mediated sphingosine-1-phosphate receptor 2 signaling exacerbates DSS-induced colitis through promoting cathepsin B release. J Immunol Res. 2018;2018:2481418.","journal-title":"J Immunol Res"},{"key":"6208_CR13","first-page":"536","volume":"7","author":"S Zhao","year":"2016","unstructured":"Zhao S, Gong Z, Zhou J, et al. Deoxycholic acid triggers NLRP3 inflammasome activation and aggravates DSS-induced colitis in mice. Front Immunol. 2016;7:536.","journal-title":"Front Immunol"},{"key":"6208_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.vascn.2003.12.002","volume":"50","author":"AR Jurjus","year":"2004","unstructured":"Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50:81\u201392.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"6208_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.MIB.0000209789.14114.63","volume":"12","author":"H Bernstein","year":"2006","unstructured":"Bernstein H, Holubec H, Bernstein C, et al. Unique dietary-related mouse model of colitis. Inflamm Bowel Dis. 2006;12:278\u2013293.","journal-title":"Inflamm Bowel Dis"},{"key":"6208_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/pathogens8030126","volume":"8","author":"I Khan","year":"2019","unstructured":"Khan I, Ullah N, Zha L, et al. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8:126.","journal-title":"Pathogens"},{"key":"6208_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2019.03.006","volume":"199","author":"K Uchiyama","year":"2019","unstructured":"Uchiyama K, Naito Y, Takagi T. Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. Pharmacol Ther. 2019;199:164\u2013172.","journal-title":"Pharmacol Ther"},{"key":"6208_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3389\/fphar.2018.01571","volume":"9","author":"PJ Basso","year":"2018","unstructured":"Basso PJ, Camara NOS, Sales-Campos H. Microbial-based therapies in the treatment of inflammatory bowel disease\u2014an overview of human studies. Front Pharmacol. 2018;9:1571.","journal-title":"Front Pharmacol"},{"key":"6208_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ibd.20392","volume":"14","author":"H Sokol","year":"2008","unstructured":"Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008;14:858\u2013867.","journal-title":"Inflamm Bowel Dis"},{"key":"6208_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","volume":"151","author":"FJ Gonzalez","year":"2016","unstructured":"Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology. 2016;151:845\u2013859.","journal-title":"Gastroenterology"},{"key":"6208_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11894-009-0057-8","volume":"11","author":"N Keating","year":"2009","unstructured":"Keating N, Keely SJ. Bile acids in regulation of intestinal physiology. Curr Gastroenterol Rep. 2009;11:375\u2013382.","journal-title":"Curr Gastroenterol Rep"},{"key":"6208_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1194\/jlr.R900007-JLR200","volume":"50","author":"PB Hylemon","year":"2009","unstructured":"Hylemon PB, Zhou H, Pandak WM, et al. Bile acids as regulatory molecules. J Lipid Res. 2009;50:1509\u20131520.","journal-title":"J Lipid Res"},{"key":"6208_CR23","doi-asserted-by":"publisher","first-page":"14691","DOI":"10.1073\/pnas.1005963107","volume":"107","author":"C De Filippo","year":"2010","unstructured":"De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691\u201314696.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6208_CR24","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/hep.29676","volume":"67","author":"P Hartmann","year":"2018","unstructured":"Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018;67:2150\u20132166.","journal-title":"Hepatology"},{"key":"6208_CR25","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1038\/ncomms5573","volume":"5","author":"X Zhou","year":"2014","unstructured":"Zhou X, Cao L, Jiang C, et al. PPARalpha-UGT axis activation represses intestinal FXR\u2013FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun. 2014;5:4573.","journal-title":"Nat Commun"},{"key":"6208_CR26","doi-asserted-by":"publisher","first-page":"357ra122","DOI":"10.1126\/scitranslmed.aaf4823","volume":"8","author":"A Rao","year":"2016","unstructured":"Rao A, Kosters A, Mells JE, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med. 2016;8:357ra122.","journal-title":"Sci Transl Med"},{"key":"6208_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","volume":"24","author":"WA Alrefai","year":"2007","unstructured":"Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24:1803\u20131823.","journal-title":"Pharm Res"},{"key":"6208_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.celrep.2014.02.032","volume":"7","author":"C Degirolamo","year":"2014","unstructured":"Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the FXR\u2013FGF15 axis in mice. Cell Rep. 2014;7:12\u201318.","journal-title":"Cell Rep"},{"key":"6208_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI76738","volume":"125","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125:386\u2013402.","journal-title":"J Clin Invest"},{"key":"6208_CR30","doi-asserted-by":"publisher","first-page":"116638","DOI":"10.1016\/j.lfs.2019.116638","volume":"232","author":"Y Duan","year":"2019","unstructured":"Duan Y, Zhang F, Yuan W, et al. Hepatic cholesterol accumulation ascribed to the activation of ileum FXR\u2013FGF15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats. Life Sci. 2019;232:116638.","journal-title":"Life Sci"},{"key":"6208_CR31","doi-asserted-by":"publisher","first-page":"63665","DOI":"10.18632\/oncotarget.18885","volume":"8","author":"L Cao","year":"2017","unstructured":"Cao L, Che Y, Meng T, et al. Repression of intestinal transporters and FXR\u2013FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer. Oncotarget. 2017;8:63665\u201363679.","journal-title":"Oncotarget"},{"key":"6208_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2012.09.048","volume":"697","author":"H Kuribayashi","year":"2012","unstructured":"Kuribayashi H, Miyata M, Yamakawa H, et al. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol. 2012;697:132\u2013138.","journal-title":"Eur J Pharmacol"},{"key":"6208_CR33","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1039\/C8FO02554A","volume":"10","author":"Q Zhai","year":"2019","unstructured":"Zhai Q, Liu Y, Wang C, et al. Lactobacillus plantarum CCFM8661 modulates bile acid enterohepatic circulation and increases lead excretion in mice. Food Funct. 2019;10:1455\u20131464.","journal-title":"Food Funct"},{"key":"6208_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7:678\u2013693.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-020-06208-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T20:33:52Z","timestamp":1616186032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-020-06208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["6208"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06208-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted with the approval of Institutional Animal Care and Use Committee at Zhejiang Chinese Medical University, Zhejiang, P. R. China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}